Related references
Note: Only part of the references are listed.
Review
Biochemistry & Molecular Biology
Ling-Yu Tian et al.
Summary: Hepatocellular carcinoma (HCC) is a major cause of cancer-related deaths globally. The dysregulation of the PI3K/AKT/mTOR signaling pathway is common in HCC, and understanding its role in regulating cellular metabolism is crucial for developing novel therapies for liver cancer.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Biochemistry & Molecular Biology
Qihang Peng et al.
Summary: Hepatocellular carcinoma (HCC) is a deadly disease with limited diagnostic and therapeutic options. This study explored the expression and potential functions of ZNF385A and ZNF346 in HCC. The results showed that ZNF385A and ZNF346 were overexpressed in HCC and correlated with poor prognosis. They were also associated with immune infiltration and decreased response to immunotherapy. Knockdown of ZNF385A and ZNF346 inhibited HCC cell proliferation and migration. These findings suggest that ZNF385A and ZNF346 could be valuable biomarkers for HCC diagnosis, prognosis, and immunotherapy response.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Review
Biochemistry & Molecular Biology
Silvia De Siervi et al.
Summary: Primary liver cancers are a major cause of cancer-related death worldwide. Three-dimensional liver organoids provide innovative models for studying the pathological mechanisms of tumors and have potential applications in regenerative medicine and drug discovery. This review discusses the current advances in liver organoids, including development protocols and possible applications.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Biochemistry & Molecular Biology
Tong Gao et al.
Summary: The downregulation of SPRED2 promotes EMT and stemness in hepatocellular carcinoma through the activation of the ERK1/2 pathway, leading to more malignant phenotypes.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Review
Biochemistry & Molecular Biology
Beatrice Foglia et al.
Summary: Hepatocellular carcinoma (HCC) is a common primary liver cancer, ranking third in cancer-related mortality worldwide. Metabolic rewiring has emerged as a key factor in HCC progression, affecting cancer cell behavior and immune responses. This review focuses on recent studies exploring HCC's metabolic traits, specifically alterations in glucose, fatty acid, and amino acid metabolism. Additionally, it examines how metabolic reprogramming can impact the tumor microenvironment and immune cell populations, enabling tumor escape from immunosurveillance.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Oncology
Rebecca L. Siegel et al.
Summary: The American Cancer Society predicts that there will be 1,958,310 new cancer cases and 609,820 cancer deaths in the United States in 2023. While incidence trends for most cancers are favorable, prostate cancer saw a significant increase of 3% annually from 2014 to 2019. However, the overall cancer death rate continues to decline due to advances in treatment, with a 33% reduction since 1991.
CA-A CANCER JOURNAL FOR CLINICIANS
(2023)
Review
Biochemistry & Molecular Biology
Hikmet Akkiz
Summary: Hepatocellular carcinoma (HCC) is a prevalent cancer that ranks fourth in cancer-related deaths globally. The tumor microenvironment (TME) formed by HCC cells and various stromal and inflammatory cells plays a crucial role in tumor growth, metastasis, and drug resistance. Cancer-associated fibroblasts (CAFs) are an important component of the TME and their signaling can contribute to drug resistance. However, CAFs display heterogeneity and can also have antitumor properties. Understanding the crosstalk between CAFs, HCC cells, and other stromal cells is essential for the development of effective targeted therapies for HCC.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Biochemistry & Molecular Biology
Hung-Wen Tsai et al.
Summary: Chronic hepatitis B virus infection is closely associated with hepatocellular carcinoma (HCC) development. The expression of a specific viral protein, large HBV surface protein (LHBS), has been found to play a significant role in tumor progression. This study developed a sandwich ELISA method to detect LHBS in serum and evaluated its association with HCC progression. The results showed that LHBS expression was correlated with HCC development and could serve as a noninvasive biomarker for predicting worse prognosis in HCC patients.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Review
Biochemistry & Molecular Biology
Emma J. Montgomery et al.
Summary: Hepatocellular carcinoma (HCC) is a common type of liver cancer and a leading cause of cancer-related death worldwide. The androgen receptor (AR) has been found to play an important role in HCC, although current AR-targeted therapies have not shown efficacy in HCC. However, by building upon research in prostate cancer (PCa), potential AR-targeted therapeutic approaches for HCC could be developed.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Biochemistry & Molecular Biology
Alessandra Scagliola et al.
Summary: Inhibition of the translation factor eIF6 can limit the progression of nonalcoholic fatty liver disease (NAFLD) to hepatocellular carcinoma (HCC), according to recent research. The study shows that reducing eIF6 levels in mice and using pharmacological inhibitors can reduce the formation and growth of HCC nodules. These findings suggest that targeting eIF6 activity could be a potential therapeutic strategy for managing NAFLD-driven HCC.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Biochemistry & Molecular Biology
Pei-Wei Shueng et al.
Summary: Sorafenib is an effective drug for hepatocellular carcinoma, but resistance often occurs. This study found that resistance to sorafenib could be reversed by inhibiting fatty acid synthesis using orlistat, and this combination treatment enhanced cell killing in hepatocellular carcinoma by altering cell metabolism.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Oncology
Hyuna Sung et al.
Summary: The global cancer burden in 2020 saw an estimated 19.3 million new cancer cases and almost 10.0 million cancer deaths. Female breast cancer surpassed lung cancer as the most commonly diagnosed cancer, while lung cancer remained the leading cause of cancer death. These trends are expected to rise in 2040, with transitioning countries experiencing a larger increase compared to transitioned countries due to demographic changes and risk factors associated with globalization and a growing economy. Efforts to improve cancer prevention measures and provision of cancer care in transitioning countries will be crucial for global cancer control.
CA-A CANCER JOURNAL FOR CLINICIANS
(2021)
Article
Gastroenterology & Hepatology
Cheng-Lung Ma et al.
